Xue Y, et al. - Data from The Cancer Genome Atlas (TCGA) was studied to recognize the potential molecular signatures to prognosticate the non-M3 acute myeloid leukemia (AML) and also to assess the relationship between miRNA expression profiles and survival of AML cases. Researchers observed that relatively younger candidates were alive at diagnosis. They found 3 miRNAs (miR-181a-2, miR-25 and miR-362) as potential biomarkers of non-M3 AML prognosis. They noted a significantly different AML outcome for individuals with lower principal component analysis (PCA) values as compared to those with higher PCA values.